DAFTAR PUSTAKA

Ainuddin, JA. 2015. Metformin for preventing gestational diabetes in women with
polycystic ovarian syndrome. J Coll Physicians Surg Pak. 2015;
25(4):237-41.
Arain, F. 2015. Frequency and outcome of treatment in polycystic ovaries related
infertility. Pak J Med Sci. 2015; 31(3):694-9.
Djuwantono, T, Tjahyadi, D, Ritonga M A. 2010. Isu Terkini Penanganan yang
Tepat Dampak Metabolik Sindroma Polikistik Ovarium. Continuing
Medical Education. Bandung: Fakultas Kedokteran Universitas
Padjadjaran.
Dumitrescu, R. 2015. Metformin-clinical pharmacology in PCOS. J Med Life.
2015; 8(2):187-92.
Foretz M., Hebrard S., Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al..
2010. Metformin inhibits hepatic gluconeogenesis in mice independently
of the LKB1/AMPK pathway via a decrease in hepatic energy state. J
Clin Invest. 2010; 120:23552369.
Foretz M., Viollet B.. 2011. Regulation of hepatic metabolism by AMPK. J
Hepatol. 2011; 54:827829.
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E.. 2012.
Metformin pathways: pharmacokinetics and pharmacodynamics.
Pharmacogenetics and Genomics, 22(11), 820827.
Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., et al..
2012. Clinical pharmacokinetics of metformin. Clin Pharmacokinet.
2011; 50:8198.
Hashim, Abu. 2015. Combined metformin-clomiphene in clomiphene-resistant
polycystic ovary syndrome: a systematic review and meta-analysis of
randomized controlled trials. Acta Obstet Gynecol Scand. 2015;
8(2):187-92.
Kim Y. D., Park K. G., Lee Y. S., Park Y. Y., Kim D. K., Nedumaran B., et al..
2008. Metformin inhibits hepatic gluconeogenesis through AMPactivated protein kinase-dependent regulation of the orphan nuclear
receptor SHP. Diabetes. 2008; 57:306314.
Maharani, L dan Wratsangka, R. 2012. Sindrom Ovarium Polikistik:
Permasalahan dan Penatalaksanaannya. J Kedokteran Trisakti. Vol 21 No
3: 98-103.
Minematsu T., Giacomini K. M.. 2011. Interactions of tyrosine kinase inhibitors
with organic cation transporters and multidrug and toxic compound
extrusion proteins. Mol Cancer Ther. 2011 ; 10:531539.
Muller J., Lips K. S., Metzner L., Neubert R. H., Koepsell H., Brandsch M.. 2005.
Drug specificity and intestinal membrane localization of human organic
cation transporters (OCT). Biochem Pharmacol. 2005 ; 70:18511860.

Naderpoor, N. 2014. Metformin and lifestyle modification in polycystic ovary

syndrome: systematic review and meta-analysis. Hum Reprod Update.
2014; 42(3):315-20.
Nies A. T., Hofmann U., Resch C., Schaeffeler E., Rius M., Schwab M. 2011.
Proton pump inhibitors inhibit metformin uptake by organic cation
transporters (OCTs). PLoS One. 2011; 6 : 22163.
Rojas, J., Chvez-Castillo M., Torres W., Arraiz N., Cabrera M., et al.. 2014.
Metformin in Cancer: Chemical Pathways for Tumoral Control
Independent of Amp-Dependent Kinase. J Endocrinol Diabetes Obes
2(2): 1036.
Somogyi A., Stockley C., Keal J., Rolan P., Bochner F.. 1987. Reduction of
metformin renal tubular secretion by cimetidine in man. Br J Clin
Pharmacol. 1987; 23:545551.
Suherman, S. K.. 2009. Insulin dan Antidabetik Oral. Farmakologi dan Terapi
Edisi 5. Jakarta : Balai Penerbit FKUI.
Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. 2008. Polymorphism in human
organic cation transporters and metformin action. Pharmacogenomics.
2008; 9:415422.
Tzvetkov M. V., Vormfelde S. V., Balen D., Meineke I., Schmidt T., Sehrt D., et
al.. 2009. The effects of genetic polymorphisms in the organic cation
transporters OCT1, OCT2, and OCT3 on the renal clearance of
metformin. Clin Pharmacol Ther. 2009; 86:299306.
Zhou M., Xia L., Wang J.. 2007. Metformin transport by a newly cloned protonstimulated organic cation transporter (plasma membrane monoamine
transporter) expressed in human intestine. Drug Metab Dispos. 2007;
35:19561962.